International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases by Boycott, K.M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/189916
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
COMMENTARY
International Cooperation to Enable
the Diagnosis of All Rare Genetic Diseases
Kym M. Boycott,1,* Ana Rath,2 Jessica X. Chong,3 Taila Hartley,1 Fowzan S. Alkuraya,4,5
Gareth Baynam,6 Anthony J. Brookes,7 Michael Brudno,8 Angel Carracedo,9 Johan T. den Dunnen,10
Stephanie O.M. Dyke,11 Xavier Estivill,12,13 Jack Goldblatt,6 Catherine Gonthier,2 Stephen C. Groft,14
Ivo Gut,15 Ada Hamosh,16 Philip Hieter,17 Sophie Ho¨hn,2 Matthew E. Hurles,18 Petra Kaufmann,19
Bartha M. Knoppers,11 Jeffrey P. Krischer,20 Milan Macek, Jr.,21 Gert Matthijs,22 Annie Olry,2
Samantha Parker,23 Justin Paschall,18 Anthony A. Philippakis,24 Heidi L. Rehm,24
Peter N. Robinson,25,26 Pak-Chung Sham,27 Rumen Stefanov,28 Domenica Taruscio,29 Divya Unni,2
Megan R. Vanstone,1 Feng Zhang,30,31 Han Brunner,32,33 Michael J. Bamshad,3,34
and Hanns Lochmu¨ller35
Provision of amolecularly confirmed diagnosis in a timelymanner for children and adults with rare genetic diseases shortens their ‘‘diag-
nostic odyssey,’’ improves disease management, and fosters genetic counseling with respect to recurrence risks while assuring reproduc-
tive choices. In a general clinical genetics setting, the current diagnostic rate is approximately 50%, but for those who do not receive a
molecular diagnosis after the initial genetics evaluation, that rate is much lower. Diagnostic success for these more challenging affected
individuals depends to a large extent on progress in the discovery of genes associated with, and mechanisms underlying, rare diseases.
Thus, continued research is required for moving toward a more complete catalog of disease-related genes and variants. The International
Rare Diseases Research Consortium (IRDiRC) was established in 2011 to bring together researchers and organizations invested in rare
disease research to develop a means of achieving molecular diagnosis for all rare diseases. Here, we review the current and future bottle-
necks to gene discovery and suggest strategies for enabling progress in this regard. Each successful discovery will define potential
diagnostic, preventive, and therapeutic opportunities for the corresponding rare disease, enabling precision medicine for this patient
population.
Introduction
Rare diseases, though individually rare,
are collectively common. A rare disease
is defined as one that affects fewer
than 200,000 people in the US1
or less than 1 in 2,000 people in
Europe.2A substantive number of rare
diseases are due to altered functions
of single genes. Cumulatively, these
rare genetic diseases (RGDs), also
termed Mendelian or monogenic
diseases, affect at least 1 in 50 individ-
uals in the European-derived general
population.3 Our understanding of
the number of RGDs that exist is
incomplete but is estimated to be well
over 7,000 according to current medi-
cal and genetic evidence4 (also see Or-
phanet in the Web Resources). Despite
their often chronic and progressive na-
ture, long-term complications can be
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lessened or delayed for some RGDs if
they are diagnosed early (e.g., via
newborn screening) and optimally
managed by standard and/or targeted
therapies. In addition, a definitive mo-
lecular diagnosis can obviate the need
for further diagnostic investigations,
facilitate appropriate access to health-
care resources, reduce prognostic un-
certainty, provide accurate recurrence-
risk counseling, foster reproductive
choices in affected families, and impart
psychosocial benefits to the patient
and their family. Importantly, under-
standing the underlying genetic etiol-
ogy and linking a RGD to a causative
biological pathway is leading to highly
effective targeted therapies for some se-
vere, previously only symptomatically
treatable RGDs (e.g., ivacaftor for class
III CFTR [MIM: 602421] pathogenic
variants).5 Ultimately, successful dep-
loyment of precision medicine will be
directly related to diagnostic success
for patients with RGDs.
Current Understanding of
Phenotypic and Genetic Diversity of
RGDs
Knowledge of the phenotypic and
genetic diversity of RGDs is steadily
increasing; however, substantial gaps
remain. Establishing the number of
RGDs is challenging for several rea-
sons, not the least of which is distin-
guishing between novel and known
diseases to objectively segment a con-
tinuum of pathologies into discrete
disease entities. Two international da-
tabases curate clinical and genetic data
for the community: Online Mende-
lian Inheritance in Man (OMIM)4
and Orphanet.6 OMIM has continu-
ously provided curation and classifica-
tion of Mendelian disease since it
began as Mendelian Inheritance in Man,
first published by Dr. V. McKusick in
1966; OMIM has been online and
searchable since 1987. OMIM mines
the biomedical literature and, accord-
ing to expert review, curates significant
new information on genes and genetic
phenotypes into separate gene and
phenotype entries. OMIM numbers
for Mendelian diseases are incorpo-
rated into the biomedical literature
across many disciplines of medicine.
OMIM emphasizes gene-phenotype re-
lationships by cataloging the same or
similar phenotypes caused by patho-
genic variants in different genes as
distinct entities; genetic heterogeneity
is displayed through the associated
Phenotypic Series. A recent analysis
of OMIM (data downloaded September
5, 2016) recognized 3,209 unique
genes associated with 4,550 mono-
genic rare diseases.
Orphanet (see Web Resources) has
maintained an inventory of both ge-
netic and other rare diseases since
1997. Within Orphanet, a rare disease
is defined as a recognizable and
homogeneous clinical presentation,
whatever the cause or the number of
genes related to it. Disorders are orga-
nized in amulti-hierarchical classifica-
tion and can be further subdivided
into subtypes, of which genetic sub-
types are included. Orphanet per-
forms a literature survey and curates
the published literature of newly
discovered genes or new gene-disease
relations. As a result, a semantic rela-
tion is assigned to couple the gene
and disease in the database. As of
September 14, 2016, Orphanet docu-
mented 3,654 unique genes associ-
ated with 3,551 rare diseases.
The discrepancy in the number of
rare diseases with monogenic etiology
documented in each of the two
databases (4,550 for OMIM and 3,551
for Orphanet) can be attributed to
the way each database is structured;
OMIM categorizes rare diseases on
the basis of genetic etiology, whereas
Orphanet groups by clinically recog-
nizable diseases and can include
more than one OMIM entry when
the same disease is caused by variants
in more than one gene. Recently, the
Clinical Genome Resource (ClinGen)7
has begun defining the strength of ev-
idence for published gene-disease asso-
ciations. The evidence levels are scored
according to semiquantitative frame-
works, and the scores are posted on
ClinGen’s website along with the
scoring sheets that structure the
evidence and sources. These scores
will also soon be posted on OMIM.
As ClinGen grows, it will enable a
clear delineation between those genes
for which gene-disease causality is
substantiated and those claims that
will require further evidence for
implication.
Although substantial progress has
been made toward identifying the
genetic basis of rare diseases, the
underlying etiologies for approxi-
mately half remain undiscovered.
Beginning in the mid-1980s, and for
the following two decades, the pri-
mary approach to gene discovery was
a combination of linkage analysis, po-
sitional cloning, and sequencing of
candidate or regionally selected genes,
most of which was hypothesis driven.
The subsequent introduction of next-
generation sequencing (NGS) strate-
gies to identify genes associated with
disease, primarily based on whole-
exome sequencing (WES), in 2009
accelerated the pace of discovery by
enabling hypothesis-free approaches.
Today, WES is routinely used as the
primary technological approach to
discovering disease-gene associations
(Figure 1). Its favor over whole-
genome sequencing (WGS) has pri-
marily been due to its significantly
lower cost and that the majority of
pathogenic variants continue to be
within the protein-coding portion of
the genome. Without a doubt, as the
cost of WGS decreases, clinicians and
researchers will transition to its use
given its more even coverage, its abil-
ity to identify structural variation,
and the opportunity it provides to un-
cover non-exomic variants.
Our analysis of OMIM documented
an average of 259 ‘‘novel’’ RGD dis-
coveries per year from 2012 to 2015
(Figure 1), comprising 157 new dis-
ease-gene discoveries (here defined as
pathogenic variants in a gene that
had not been previously associated
with disease) and 102 new disease-
gene relations each year (defined
as pathogenic variants in a gene
previously associated with a different
disease; data not shown).8 Orphanet
documents an average of 281 novel
RGD discoveries per year over the
same time period: 160 new disease-
gene discoveries and 121 new
disease-gene relations (Figure 2). Or-
phanet and OMIM report essentially
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the same number of new disease-gene
discoveries (average of 160 and 157,
respectively, over the same time
period), but more disease-gene rela-
tions have been reported by Orphanet
(121 versus 102 for OMIM). In a
manual review of randomly selected
discrepancies between OMIM and
Orphanet, this is most likely attribut-
able to differences in the process of
curation; OMIM is more likely to
decide that the publication reports a
phenotypic expansion of an already
explained RGD than a new disease-
gene relation. Nevertheless, the data
from OMIM and Orphanet both
show that a significant proportion of
RGD discoveries are new diseases asso-
ciated with pathogenic variants in
previously known genes (gene-disease
relations): 38 and 43%, respectively.
This is an interesting trend in compar-
ison with a recent analysis of all of
OMIM’s data, which demonstrated
that nearly 25% of all genes associated
with Mendelian disease underlie two
or more clinically distinct disorders.8
Since the introduction of WES,
many RGDs that were previously
intractable to conventional gene-dis-
covery approaches, largely because
they were associated with a substan-
tially reduced reproductive fitness,
have been found to be caused by de
novo pathogenic variants or to exhi-
bit high allelic or locus heterogeneity.
These RGDs are enriched with highly
recognizable clinical presentations;
are often associated with early age of
onset, severe phenotype, and/or clear
laboratory and/or medical imaging
features; and are caused by highly
penetrant pathogenic, protein-coding
genomic variants (i.e., in legacy termi-
nology, ‘‘mutations’’). In addition,
these RGDs are usually autosomal,
X-linked recessive, or de novo domi-
nant, rendering them relatively more
accessible and amenable to current
discovery strategies relying on WES;
these RGDs represent the sweet
spot of WES-based approaches. Both
OMIM and Orphanet data (Figures 1
and 2) show a trend toward a de-
creasing number of discoveries per
year; whether this trend is real or
will continue will require analysis of
data from future years. However,
what is clear is that recognized bottle-
necks must be addressed if the current
pace of discoveries is to be main-
tained, or even accelerated, after the
more straightforward RGDs have
been solved.
The International Rare Diseases
Research Consortium
The International Rare Diseases Re-
search Consortium (IRDiRC) was es-
tablished in 2011 to bring together
researchers andorganizations invested
in rare disease research. Three IRDiRC
Scientific Committees (Diagnostics,
Interdisciplinary, and Therapies) and
representation from three patient-
advocacygroups (two fromtheUS [Na-
tional Organization for Rare Disorders
(NORD) andGenetic Alliance] andone
from Europe [Rare Diseases Europe-
EURORDIS]), advise the Consortium
Assembly (formerly the Executive
Committee), which includes public
research funders and private-sector
members from pharma and biotech
from 42 member institutions. Each
has committed at least $10,000,000
USD to rare disease research within
their jurisdiction (Figure 3; data ac-
cessed January 11, 2017). Currently,
rare disease research coordinated
under the umbrella of IRDiRC totals
more than $2,000,000,000 USD.
IRDiRC aims to facilitate the under-
standing of all rare genetic diseases.
The focus of the Diagnostics and
Interdisciplinary Committees, and
their associated working groups
and task forces, has been identifying
current and future bottlenecks to
RGD discovery and suggesting strate-
gies by which international coopera-
tion can address them. We anticipate
that several shortcomings of the pre-
sent-day discovery pipeline will need
to be addressed if we are to continue
to make important RGD discoveries
at the current pace, or even accelerate
it. These include the collection and
analysis of clinical and genomic
data, data discovery and sharing, ge-
netic and functional support for the
establishment of disease causality,
and the presence of disease mecha-
nisms that are intractable to our cur-
rent analytical and genomics-based
approaches, as summarized in Table 1.
Strategies for Enabling the
Diagnosis of All RGDs
The coming years will see an expanding
need for large-scale infrastructure, re-
sources, and tools for completing the
grand challenge: understanding the
molecular pathogenesis of all RGDs.
Over the past few years, our commit-
tees, working groups, and task forces
have identified specific areas of high
Figure 1. Approximate Number of Gene Discoveries Made by WES and WGS versus
Conventional Approaches since 2010 according to OMIM Data
Since the introduction of WES and WGS in 2010, the pace of the discovery of genes un-
derlying RGDs per year has increased, and the proportion of discoveries made by WES or
WGS (blue) or by conventional approaches (red) has steadily increased. Since 2013, WES
and WGS have discovered nearly three times as many genes as conventional approaches,
but the rate of discovery appears to be declining. Adapted from Chong et al.8
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priority to facilitate the achievement of
this goal. To this end, the IRDiRC has
developed a quality indicator, ‘‘IRDiRC
Recognized Resources,’’9 on the basis
of specific criteria to highlight key re-
sources (e.g., platforms, tools, stan-
dards, and guidelines), which, if used
more broadly, would accelerate the
pace of discoveries.
Ontologies, Terminologies, and Nosol-
ogies for Exchanging Clinical Data
Understanding how genomic alter-
ations result in different disease-related
phenotypes is fundamental to human
health research. In this endeavor, if
careful phenotypic characterization is
lacking, having genomic data, even
from large numbers of individuals, is
of limited value. Although we have
made large strides toward enabling
the sharing of genotype data, stan-
dards are not widely used for the ex-
change of phenotypic data. For undi-
agnosed RGDs, the situation is even
more problematic because only a few
individuals in the world might have
the same undiagnosed condition.
Currently, numerous ontologies, termi-
nologies, and nosologies are used,
reflecting the disparate needs and prac-
tices of different communities involved
in translational research and patient
care in many fields of medicine.
The IRDiRC recognizes phenotype
ontologies, terminologies, and disease
nosologies as critical for RGD research.
The Human Phenotype Ontology
(HPO)10,11 has been recognized as a
useful annotation of phenotypic ab-
normalities of RGDs, with the under-
standing that other resources might
be suitable in certain situations, and is
being used by RGD databases such as
PhenomeCentral,12 DECIPHER,13 the
UK10K Project,14 and many others.
The HPO has been incorporated into
the United Medical Language System
(UMLS), which will allow interopera-
bility with an even larger range of med-
ical informatics resources. The HPO is
more than a clinical terminology; all
terms are set in a hierarchical structure,
and it is designed to allow computa-
tional analysis of clinical findings
for differential diagnostics,15 as well as
RGD phenotypic stratification prior
to WES analysis in both the clinical16
and discovery settings.17 A key area
for ontological development is in-
creasing the granularity and coverage
of the HPO across some less well-
covered rare-disease domains. Addi-
tionally, enabling a means of making
longitudinal assessments (onset and
temporality), utilizing phenotype nega-
tion (the patient does not have pheno-
type X), and making quantitative spec-
ifications (e.g., levels of abnormality of
laboratory results) will be important.
To bridge the compatibility gap
between various systems and the lack
of terminology specific enough for
RGDs, the newly established Interna-
tional Consortium for Human Phe-
notype Terminologies (ICHPT) has
worked to provide the community
with phenotype terminology stan-
dards and definitions for the more
often used phenotype terms for data-
base interoperability, in particular to
allow the linking of phenotype and ge-
notype databases for RGDs. The ICHPT
was created with input from members
of several groups, including Orphanet
(under the EuroGentest project; see
Web Resources), HPO,18 and OMIM
(Robinson et al., 2014, Am. Soc.
Hum. Genet., abstract). The outcome
of this effort is a set of >2,300 terms
that should be present in any termi-
nology through one of its synonyms.
These terms have already been map-
ped to a few of the major terminol-
ogies, including HPO,11 PhenoDB,19
Orphanet, Elements of Morphology,20
POSSUM, SNOMED, MeSH, and
MedDRA, facilitating cross-compati-
bility between systems. Where ontol-
ogies contain more detailed terms at
a finer level of granularity, these terms
will map ‘‘up’’ to the broader aligned
terms. The IRDiRC recognizes and en-
courages the ICHPT as the minimal
set of standard terms to be used for
sharing phenotypic data.
Two complementary rare-disease no-
sologies exist, the Orphanet Rare Dis-
ease Ontology (ORDO)21 and OMIM.4
ORDO is a structured vocabulary for
rare diseases and is derived from the
Orphanet database; it captures relation-
ships between diseases, genes, and
other relevant features to form a useful
resource for the computational analysis
of rare diseases. It integrates nosologies
(classifications of rare diseases), relation-
ships (gene-disease relations and epide-
miological data), and connections with
other terminologies (MeSH, UMLS,
and MedDRA), databases (OMIM,
UniProtKB, HGNC, Ensembl, Reac-
tome, IUPHAR, and Geneatlas), or clas-
sifications (e.g., International Statistical
Classification of Diseases and Related
Health Problems-10 [ICD-10]). It should
be noted that ICD-10 contains only
500 unique rare-disease classification
codes. This deficiency is now being
overcome by the development of a
Figure 2. Approximate Number of Novel Gene-Phenotype Discoveries from 2010 to
2015 according to Ophanet Data
Since 2010, the proportion of discoveries that are new disease-gene relations each year
(known genes associated with a new disease) has steadily increased. Since 2013, the
rate of discovery of both novel genes and new disease-gene relations appears to be
declining.
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hierarchical rare-disease classification
and coding (Orpha numbers) scheme
by Orphanet, which will become the
basis for inclusion of the majority of
known rare diseases into ICD. Orpha
numbers are now increasingly used
by European healthcare systems for
informatics tracing of RGDs, and their
introduction is fostered by National
Action Plans and Strategies for Rare
Diseases and recommended by the Eu-
ropean Commission expert group on
rare diseases.22
OMIM has also played a central role
in the naming and classification of
Mendelian diseases by defining recog-
nizable patterns of features and
highlighting those that allow one
condition to be distinguished from
another. In general, OMIM creates
separate phenotype entries on the ba-
sis of molecular etiology, that is, ge-
netic heterogeneity. OMIM’s clinical
synopsis for each phenotype includes
only those features that have been
reported in individuals with muta-
tions in the disease-associated gene.
Each OMIM phenotype is assigned a
unique and stable identifier (MIM
number) that is used in the aforemen-
tioned databases and in the biomed-
ical literature. The IRDiRC strongly
supports the continued interopera-
bility between the rare-disease nosol-
ogies ORDO and OMIM, both of
which are recognized for rare-disease
classification.
Standards, Tools, and Resources to
Facilitate Genomic Data Analyses
Our ability to analyze, annotate, and
ultimately share genomic datasets is
fundamental to the RGD research
agenda. Currently, tools and methods
for analysis and annotation are not
standardized and lack interopera-
bility; as a result, the sharing of out-
puts from large genomic datasets is
hampered. Pipelines for analyzing
DNA sequences still have much
room for improvement in terms of
sequence alignment, variant calling,
and functional annotation and pre-
diction, especially for more complex
variation such as insertions, deletions,
and the wide spectrum of structural
variants,23 calling for a harmonized
approach. This observation is sup-
ported by recent data suggesting
that the limited yield of WES as re-
ported in the literature, at least in
the context of certain recessive dis-
eases, is mostly accounted for by our
limited ability to correctly call vari-
ants.24 An example of such a platform
has been developed by the RD-Con-
nect EU project for research and diag-
nosis, together with the EURenOmics
andNeurOmics RGD research projects.
Furthermore, existing tools will need
to be made interoperable and widely
adopted, and their curation and up-
dates should be duly coordinated.
Genomic data analyses for RGD dis-
covery are also challenged by the
identification of rare variants to be
prioritized for further interpretation.
Investigators studying the causes of
RGDs are relying heavily on WES
datasets compiled by consortia, such
as the Exome Aggregation Con-
sortium (ExAC; 60,000 exomes) and
the NHLBI Exome Sequencing Project
(ESP; 6,500 exomes), that investigate
different diseases as reference datasets
for analyses, and this is proving useful
in decreasing the number of variants
to a manageable number for certain
populations. However, many of these
first comparative exome datasets
have been generated from popula-
tions of Western European and North
American origin. This limits patho-
genic variant discovery, especially
from populations that have been
sparsely assessed, if sampled at all.
The 1000 Genomes Project has made
significant contributions to our un-
derstanding of the architecture of
the human genome as a large hete-
rogeneous population dataset. Most
recently, gnomAD has aggregated
15,000 genomes and 120,000 exomes,
including data from the 1000 Ge-
nomes Project and the ExAC and ESP
exome datasets. Increasing such pop-
ulation datasets and generating and
sharing datasets from populations
with little to no representation in ex-
isting repositories that can be used
by the RGD research community, as
well as others investigating human
health, will be of great importance in
the future. The Global Alliance for
Genomics and Health (GA4GH) is
active in this space and is committed
to enabling responsible and effective
sharing of genomic and clinical
data through a federated ecosystem
approach; we support these efforts
and their application to RGDs.25
For example, the Beacon Network, a
demonstration project of GA4GH, is
a global search engine for genetic
Figure 3. Map of the IRDiRC
The IRDiRC was formally launched in 2011 and currently includes member institutions
from Asia, the Middle East, Australasia, Europe, and North America. The current cumula-
tive commitment from the 42 member institutions from both the public and private sec-
tors is estimated at more than $2,000,000,000 USD.
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variation and connects 60 databases
representing every inhabited conti-
nent, enabling global discovery of ge-
netic variation.
Ethical Standards to Enable Data Dis-
covery and Sharing
The RGD research community is
acutely and universally aware of the
need for data discovery and sharing.26
Given the challenge ahead of us to un-
derstand and be able to diagnose RGDs
of ever increasing rarity, the ability to
share clinical and genetic data maxi-
mally has become of central impor-
tance. In this regard, the IRDiRC is
collaborating with the Human Vari-
ome Project (HVP) and GA4GH to
tackle major ethical, legal, and social
issues and agree on standards for
international data to break down exist-
ing hurdles. The IRDiRC has recog-
nized the Framework for Responsible
Sharing of Genomic and Health-
Related Data27 as a resource on the
basis of international adherence to
Article 27 of the UN Declaration of
Human Rights, which holds that
everyone has a right ‘‘to share in scien-
tific advancement and its benefits’’ and
‘‘to the protection of the moral and
material interests resulting from any
scientific . production of which [a
person] is the author.’’28 Recently, rec-
ommendations and models for ‘‘Data
Transfer Agreements’’ have been pub-
lished with the ‘‘IRDiRC recognized’’
label.29
The IRDIRC-HVP-GA4GH collabo-
ration is paving the way for interna-
tional recognition of common data-
sharing standards. Several critical
areas of data-sharing governance are
currently the focus of collaborative
efforts. First, the collaboration devel-
oped a ‘‘tiered’’ consent policy that
is dependent on the context of
data collection and use (clinical or
research) and on the level of risk that
the shared data will be identified;
this policy is currently in use by
the Matchmaker Exchange30,31(MME;
see below). Two related initiatives,
namely the Consent Codes32 model
and the Automatable Discovery and
Access Matrix (ADA-M), seek to enable
systematized representation of con-
sent-, legal-, and institutional-based
permissions and restrictions associ-
ated with research and clinical records
to facilitate streamlined and appro-
priate discovery, sharing, and use of
extant datasets. This will also help
to better standardize consent-form
clauses, thereby guiding best practices
in both research and ethics review
committees. Just as consent practices
need to become interoperable so as
to enable greater data sharing, so too
do data-access mechanisms. Efforts
are currently underway to produce a
new model that would facilitate data
access (registered access) and use inter-
actions with initiatives such as MME
by authorizing users through a stan-
dard online authentication and attes-
tation process. Registered access will
address different categories of poten-
tial data users (researchers, clinical
care professionals, and patients), as
well as different levels of data depend-
ing on their identifiability and sen-
sitivity. Additional IRDiRC-GA4GH
collaboration is underway to develop
a privacy-preserving linkage system
that would link data from the same
individual across multiple projects
while also respecting privacy. Policy
for recognizing ethics review to en-
courage streamlined and coherent
ethics review for international pro-
jects and consortia is also available.
Over time, such efforts will harmonize
local ethical, legal, and social policies
and procedures for efficient and
responsible international sharing and
analysis of genomic and clinical data.
Genetic Evidence to Support Gene
Discovery
Reports from several large-scale col-
laborative research initiatives, in-
cluding the FORGE Canada Con-
sortium,33 US Centers for Mendelian
Genomics,8 and UK Deciphering
of Developmental Disorders study,34
indicate that under very select
circumstances (including ascertain-
ment of multiple, thoroughly pheno-
typed families with the same condi-
tion), the ‘‘solve rate’’ for RGDs
is often >50%. Reports focusing
on disease-causing variants in known
Table 1. Factors Contributing to Bottlenecks in the Gene-Discovery Pipeline
Clinical data d non-specific clinical presentations (e.g., developmental delay and
hypotonia)
d ultra-rare and unrecognized genetic diseases
d lack of ontology encompassing the complete spectrum of human
phenotypes
d insufficient utilization of ontologies or 3D facial-gestalt analysis in
phenotyping
d inconsistent multidisciplinary approaches to patient evaluation
d inability to account for and compare age-specific disease presen-
tations
Genomic data d technical limitations of WES (e.g., copy-number variants and
structural variation are not captured well)
d lack of standardized technical and informatics approaches
d incompleteness of population-specific control datasets
Data discovery
and sharing
d lack of a widely adopted data-sharing framework
d lack of common data-sharing standards
d lack of a systematic way to record data-use conditions
d lack of a privacy-preserving linkage system for each research
participant
Genetic evidence d siloed datasets
d lack of and use of data-sharing infrastructure
Functional evidence d lack of standardized and moderate-throughput analyses of variant
impact
d lack of biological insight into the function of most human genes
Novel disease
mechanisms
d lack of expertise in the analysis of non-coding variants
d other mechanisms including tissue-specific mosaicism, methyl-
ation, and di- or oligogenic inheritance
700 The American Journal of Human Genetics 100, 695–705, May 4, 2017
disease-related genes in over 9,000
cases from various clinical diagnostic
settings indicate an overall success
rate of 30%.35–39 These latter co-
horts have demonstrated that a sub-
stantial fraction (25%–30%) of clin-
ical diagnostic success depends on
recent progress in the discovery of
genes underlying disease. This obser-
vation in combination with the
higher solve rate in the research
setting suggests that the unsolved
fractions of these clinical cohorts
contain many discoveries.
Case-Based Matching for Gene
Discovery. The discovery of disease-
gene associations requires confirma-
tion of pathogenic genomic variation
in multiple unrelated individuals
affected by the same rare disease.
Our collective experience suggests
that it takes approximately 2–3 years
to identify an additional unrelated in-
dividual with likely pathogenic muta-
tions in the same gene after publica-
tion of a single patient or family.
Thus, a central challenge is to effi-
ciently identify additional and unre-
lated persons with pathogenic vari-
ant(s) in the same gene and an
overlapping phenotype. It is difficult
to gauge the number of such single
surviving candidate genes (containing
deleterious-appearing genetic varia-
tion that remains after multiple fil-
tering steps with segregation data
and pathway and/or model-organism
support from existing literature) that
remain unpublished and/or in inac-
cessible ‘‘silos’’ worldwide, but we esti-
mate it to be more than 1,000.
To address this challenge, several
collaborative initiatives have devel-
oped platforms for genotype- and
phenotype-driven matching algo-
rithms12,13,40–52; however, a connec-
tion between these existing solutions
has been lacking. Very recently, the
IRDiRC Diagnostics Scientific Com-
mittee, in collaboration with each
participating data-sharing service,
Can-SHARE, and the GA4GH, has
contributed to launching a federated
platform termed the MME.53 This
platform facilitates the identification
of unsolved patients and families
with similar phenotypic and geno-
typic profiles through a standardized
application programming interface
(API) and standard operating proced-
ures.40 The MME enables searches of
multiple databases at once, circum-
venting the need to separately search
all services by depositing data in
each one. Under this initial API,
each server can treat any description
arbitrarily: the level of similarity
required (on either the genotype or
phenotype level) before a match is
triggered is left to the discretion of
each service. The launch of the MME
is a major step forward, and currently
PhenomeCentral,12 GeneMatcher,41
DECIPHER,13 MyGene2,54 matchbox,
and Patient Archive, representing
data frommore than 20,000 unrelated
RGD patients, are connected to one
another. However, truly optimizing
this type of case-based matching and
enable RGD discovery on a global
scale will require improvement of in-
ternational data sharing, optimiza-
tion, financial support, and scaling
up of such infrastructure, operating
procedures, and algorithms.
Functional Evidence to Support Gene
Discovery
Integration of Genomic Data into Sys-
tems Biology. Parallel to the enormous
advances in gene identification
throughWES, other large-scale -omics
approaches have been developed (e.g.,
proteomics, transcriptomics, and me-
tabolomics) to aid RGD discovery
and facilitate the validation of vari-
ants of unknown significance. For
instance, changes in protein levels or
function help to identify the disease-
causing variant if more than one
plausible gene has been identified
through WES. Data integration across
different -omics datasets on popula-
tion or individual patient levels will
also be required for understanding
the importance of disease-modifying
variants in conditions with high
phenotypic variability or incomplete
penetrance and for assisting the
development of diagnostics and ther-
apeutic biomarkers and will play an
increasing role in developing targeted
therapies. For example, RD-Connect is
establishing a platform where geno-
mic data on rare disease patients are
combined with other -omics data
and standardized phenotypes.55 Such
initiatives need to be increased in
number and made sustainable.
Model Systems to Facilitate Gene
Discovery. Model-systems research (in
humans, yeast, flies, worms, zebrafish,
mice, and other organisms) will
continue to be critical in determining
the functional consequences of geno-
mic variants in candidate disease-
related genes and in discovering and
validating new drug targets, candidate
drugs, and other therapeutic strate-
gies. The pace of allele discovery is
outstripping our ability to understand
the biological consequences of indi-
vidual mutations on gene, pathway,
and network function. There is an
opportunity for the next generation
of disease modeling to address this
gap in an efficient, cost-effective, and
generalizable manner with higher
throughput. Improved infrastructure
is required for (1) allowing clinician
scientists who have discovered a dis-
ease-causing variant to be exposed to
the full range of experimental tools
available to them, (2) allowing experts
in a variety of model organisms to
apply their skills on pertinent ques-
tions of biological and clinical inter-
est, and (3) creating efficiencies so
that studies are not duplicated and
existing models are utilized to their
full potential. Linking clinician scien-
tists and basic researchers early and
providing seed funds for collaborative
experiments would be the ultimate
goals of such an effort.
One approach to accelerating col-
laborations between clinicians and
basic researchers is to proactively iden-
tify collaborative ‘‘matches’’ and to
provide seed funding to ignite col-
laborative research projects. In Can-
ada, a national infrastructure, the
‘‘Rare Diseases: Models and Mecha-
nisms’’ network, has been established
to link clinicians and basic researchers
as soon as disease-related genes are
discovered.56 The network is in its sec-
ond year of its 3 year funding cycle
and has been successful in catalyzing
collaborative links for over 40 clinician
and basic-scientist matches. An alterna-
tive approach is through an ‘‘enabling’’
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scheme, in which national funding
agencies allow investigators to jointly
apply for supplemental funding to
existing grants. In the US, for example,
administrative supplements to ‘‘R’’
and ‘‘P’’ grants are not uncommon;
indeed, this model has been used by
the NIH Undiagnosed Disease Program
to seed research on candidate genes
discovered by that effort.57 An inte-
grated international virtual network
allowing clinician scientists to discover
relevant researchers might also be
a complementary and intermediate
approach.
It will also be important to stimu-
late the establishment and validation
of novel phenotyping pipelines that
have correlates in other organisms by
emphasizing disease relevance, patho-
physiological pathways, and high
efficiency. This will accelerate the
evaluation of genomic variants and
candidate genes, drug and drug-target
testing using disease-relevant output
measures, and fundamental under-
standing of disease mechanisms and
pathologies. Phenotyping pipelines
can, in some cases, assess disease traits
that resemble hallmarks of the human
disorder in an obvious manner (e.g.,
malformations, behaviorial features,
or other findings). If sufficiently
specific (i.e., unique), such pheno-
types can validate the relevance of a
disease model. TheMonarch Initiative
has been working in this realm since
2009 and acts as an integrative data
and analytic platform that connects
phenotypes and genotypes across spe-
cies. Alternatively, phenotyping pipe-
lines can assess traits that are not
linked to the disease of interest in an
obvious manner but that do result
from the same molecular defects un-
derlying the disease phenotype in hu-
mans and thus represent orthologous
phenotypes (‘‘phenologs’’).58 In addi-
tion, it will be important to develop
and validate novel efficient and dis-
ease-relevant test paradigms and phe-
notypes that can be cross-compared
between species (parallel phenotyp-
ing). Such validated disease-relevant
phenotypes across organisms could
provide the required output measures
for overcoming current bottlenecks,
such as the validation of alleles and
disease-related genes, at a scale that
is urgently required in the post-
genome-sequence era.
Novel Disease Mechanisms
Progress toward the discovery of the
genetic basis of every RGD has been
substantial over the past several years.
Yet, there remain a non-trivial num-
ber of well-known rare diseases (e.g.,
Hallerman-Streiff syndrome, Dubo-
witz syndrome, VACTERL, Gomez-Lo-
pez-Hernandez syndrome, Aicardi
syndrome, and PHACE syndrome)
for which, despite multiple groups’ ef-
forts to use WES and, in some cases,
WGS, the causal genetic mechanism
remains elusive. The reasons that
such discovery efforts fail are myriad
and most likely include both tech-
nical limitations (e.g., annotation er-
rors, missed coding and non-coding
variation, and structural variation)
and complex biology (e.g., extreme lo-
cus heterogeneity, tissue-specific so-
matic mosaicism, unusual modes of
inheritance, intrafamilial allelic or lo-
cus heterogeneity, and causal synony-
mous variants). Approaches that over-
come these barriers to RGD discovery
are few in number. Moreover, the
rare genetic conditions for which the
genetic mechanism has yet to be
identified are likely enriched with
those that will not be solved easily
by existing WES-based approaches.
Identifying the molecular basis of
conditions intractable to existing ap-
proaches requires broader and in-
novative application of existing dis-
covery strategies (e.g., WGS, RNA
sequencing of affected cells or tissues,
and deep sequencing of tissues deri-
ved from the three major embryonic
lineages); improvement of compu-
tational and statistical models for
variant identification, annotation,
functional prediction, and prioritiza-
tion—particularly for variants in
non-coding regions;59 and develop-
ment of strategies for discovering causal
genetic mechanisms. Also, temporally
focused, multidisciplinary assessments
that take advantage of cumulative
expert clinician experience and preci-
sion phenotyping centered around sin-
gle patients, such as the Undiagnosed
Diseases Network International,60 are
part of a suite of approaches to support-
ing the discovery of rare-diseasemecha-
nisms. The development and applica-
tion of these strategies will further
leverage investments that support
genetic and functional approaches for
the discovery of underlying genetic
mechanisms.
Critical Next Steps
Achieving the IRDiRC’s goal of a
means of diagnosing all RGDs will
require the discovery of the genetic
mechanism underlying every dis-
order. This challenge—producing a
complete catalog of the phenotypic
characteristics of all RGDs and their
corresponding causal variants, devel-
oping successful approaches to dis-
covering the underlying etiology of
RGDs caused by non-traditional
modes of inheritance, and establish-
ing tools and resources to translate
this new knowledge into patient care
(e.g., harmonization and adoption of
international guidelines for the clin-
ical application of NGS-based ap-
proaches)—is significant. This grand
challenge can be achieved only with
significant international cooperation
and engagement of all relevant stake-
holders at a scale the community has
never seen before. Efforts to engage
the research community, such as the
IRDiRC and GA4GH, are of critical
importance, and international coordi-
nation and funding of activities will
be necessary. Improving translation
and reimbursement strategies for clin-
ical genome-wide analysis of patients
with rare diseases will be essential;
this is particularly important for
avoiding the large number of patho-
genic variants identified in known
genes in research projects focused on
discovery and reallocating research
funding to the generation and valida-
tion of novel insights. Engaging clin-
ical laboratories, researchers, and the
patient community to share their
data will be critical.
We must also recognize that as
more and more genes are discovered
to be associated with human disease
and appropriate analytical tests are
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established, a significant challenge in
RGD diagnosis will remain: that of in-
terpreting a growing numbers of vari-
ants of uncertain significance. DNA
diagnostics for RGD is primarily based
on shared knowledge about genes,
genomic variation, and phenotypes.
Currently, diagnostic data are col-
lected through a multitude of ap-
proaches by many different diag-
nostic laboratories and are stored in
a wide variety of server systems and
databases, which generally lack feder-
ated connections, i.e., ‘‘silos.’’ Local
solutions need to be developed and
implemented for storing data on ge-
netic variants and their associated
phenotypes in an easy and reproduc-
ible way with common standards
and terminologies. In addition, these
local systems need to be connected
worldwide to form a ‘‘genetics knowl-
edgeweb.’’ Making this type of sharing
part of the normal standard of care will
require community engagement. Inte-
grating existing platforms that store
clinical genetic and phenotype data
(e.g., ClinVar,61 LeidenOpenVariation
Database [LOVD],62 andDECIPHER13),
linking different types of data (e.g.,
array and sequencing), and encom-
passing small (single-nucleotide) to
large (deletion, duplication, inversion,
etc.) variants will be essential. These
challenges are further compounded
by the rate and impact of false-positive
causative variant assignments63 that
exist in such databases, so ultimately
the curation of this knowledge by rele-
vant experts will be the key to diag-
nostic precision. Variant classification
as pathogenic or benign will rely
heavily on the same tools that are
critically needed for RGD discovery,
specifically the availability of popula-
tion-specific disease and control data-
bases for a diverse range of popula-
tions, the use of orthogonal assays
such as metabolomics, transcriptom-
ics, or proteomics to clarify func-
tional effect, and the systematic
screening of mutations in disease-
related genes in tractable models or
cell systems. Clearly, the task of as-
signing pathogenicity to individual
variants is mission critical to infor-
med patient care.
Achieving a means of diagnosing all
RGDs will be of great importance for
patients and families. It will allow ge-
netic counseling, better prognostica-
tion, and identification of specific
health risks to the individual and will
prevent unnecessary or harmful diag-
nostic interventions and treatments.
Ultimately, such insights can be
applied to genome-wide sequencing
in newborns for both diagnosis and
screening.64 In an increasing number
of patients, effective drug treatment
is available once the exact diagnosis
(e.g., lysosomal-storage disorders or
congenital myasthenic syndromes)
has been established.65 In addition,
this aim will allow more patients to
participate in research cohorts for
clinical trials that require a definite
molecular and phenotypic diagnosis,
providing potential benefit from new
drugs or interventions being devel-
oped by academia and the private
sector.66 In our view, the understand-
ing of all RGDs will be the cornerstone
of precision medicine; the power of
genomics to explain these rare dis-
eases with concomitant fundamental
insights into biological processes will
rapidly transform medical care for
these patients and their families.
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